TORNTPHARM Torrent Pharmaceuticals Q3 FY25 results (Oct–Dec 2024) and concall
Management summary
- Torrent Pharma delivered a resilient Q3 FY25, characterized by strong outperformance in the India branded chronic segment and a recovery in the insulin CMO business.
- While headline revenue growth was muted at 3% due to temporary insulin facility downtime and Brazilian currency depreciation, underlying EBITDA growth remained healthy at 12% on a normalized basis.
- Management remains focused on margin expansion and strategic entries into the GLP-1 market by 2026.
Source: Inve concall analysis and management guidance record.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 2,377 |
| EBITDA | 887 |
| Net profit | 485 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Margin
Operating EBITDA Margin Margin · FY25 · High confidence 32.5%
Previously 31.4% → 32.5%
Annual Margin Improvement Margin · Annually · Medium confidence 50-100 bps
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Insulin CMO Recovery and Margin Impact Direct
So, over and above run rate of 75-80, there should be a significant spillover which you will see in Quarter 4.
Confirms that the Q3 revenue drag was temporary and will reverse with high-margin spillover in Q4.
Asked by Damayanti Kerai, HSBC
Brazil Currency Depreciation vs. Price Increases Direct
I would be expecting a higher level of price increase allowed to us by the government, more in the close to the double-digit number as compared to middle or single digit in the last three, four years.
Management expects government-mandated price hikes in April to offset the significant BRL depreciation impact.
Asked by Damayanti Kerai, HSBC
Unlock risks & concerns, Q4 FY25 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- Watchlist triggers for Q4 FY25
- +3 more guidance targets & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





